Comparative Pharmacology
Head-to-head clinical analysis: BIMATOPROST versus MISOPROSTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIMATOPROST versus MISOPROSTOL.
BIMATOPROST vs MISOPROSTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It binds to prostaglandin F (FP) receptors on ciliary muscle cells and trabecular meshwork cells, increasing uveoscleral outflow and possibly trabecular outflow of aqueous humor, thereby reducing intraocular pressure. It also directly stimulates the prostaglandin FP receptor, leading to increased matrix metalloproteinase activity and remodeling of the extracellular matrix in the ciliary body.
Misoprostol is a synthetic prostaglandin E1 analog that induces uterine contractions and cervical ripening by binding to prostaglandin receptors, leading to increased intracellular calcium and myometrial contraction. It also inhibits gastric acid secretion by reducing parietal cell activity and protecting gastric mucosa via increased bicarbonate and mucus production.
One drop of 0.01% or 0.03% ophthalmic solution instilled into the affected eye(s) once daily in the evening.
200 mcg orally four times daily (with meals and at bedtime) for prevention of NSAID-induced gastric ulcers; 800 mcg sublingually every 4 hours for up to 3 doses for labor induction; 25 mcg orally single dose for cervical ripening.
None Documented
Clinical Note
moderateBimatoprost + Unoprostone
"Bimatoprost may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateBimatoprost + Hydrochlorothiazide
"Bimatoprost may increase the hypotensive activities of Hydrochlorothiazide."
Clinical Note
moderateBimatoprost + Epoprostenol
"Bimatoprost may increase the hypotensive activities of Epoprostenol."
Clinical Note
moderateVardenafil + Bimatoprost
"Vardenafil may increase the antihypertensive activities of Bimatoprost."
None Documented
Terminal half-life: ~45 minutes (intravenous); after topical ocular administration, systemic half-life is similar due to rapid systemic clearance, with clinical effect lasting 24 hours due to ocular tissue binding
2-3 hours for misoprostol acid (active metabolite); clinically, a short duration requires multiple daily dosing. In patients with renal impairment, half-life may be prolonged but not significantly clinically.
Renal: <67% (unchanged and metabolites), Biliary/fecal: ~25%
Primarily renal excretion of metabolites; ~80-90% of a radiolabeled dose is excreted in urine within 24 hours, with the remainder in feces. Misoprostol acid (active metabolite) undergoes further beta-oxidation and reduction; <1% excreted unchanged.
Category C
Category D/X
Prostaglandin Analog
Prostaglandin Analog